What the changes say
- Commercial-scale validation is now the central technology risk; Terrebonne remains only a small research and development plant.
- India facility execution now directly affects Nike, Taro Plast, Shinkong and Hyosung TNC agreements.
- India facility funding estimate fell to $165–$170 million, while its commercial-start date is no longer assured.
- Net loss declined from $15.1 million to $12.2 million, but limited revenue and continuing losses remain.
What changed since the prior 10-K
New
- NewRISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
Our technology may not be successful in achieving widespread commercial success at scale
The technology has not yet been tested at the scale or cost structure needed for large commercial facilities, including India and Europe.
Dropped
- DroppedRISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
Our technology may not be successful in developing commercial products
- DroppedRISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
Disruption at, damage to, or destruction of our Terrebonne Facility could impede our ability to continue innovating and refining our technological process, and supporting our commercial projects, which would harm our business, financial condition, and operating results
Reworded
- 66% rewrittenRisks related to this joint venture and facility construction include, but are not limited to
Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities
The risk now highlights a new $15.0 million ATM share offering through Roth, alongside the existing $175.0 million shelf.
- 62% rewrittenRisks related to this joint venture and facility construction include, but are not limited to
Failure to achieve expected operating efficiencies or projected economic returns
The risk now identifies dependence of Nike, Taro Plast, Shinkong and Hyosung TNC agreements on the India facility’s performance.
- 40% rewrittenRISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
Our joint venture with Ester to construct and operate a manufacturing facility in India involves significant risks, and any delays or disruptions could adversely affect our business, financial condition, and prospects
India’s estimated initial funding requirement decreased from approximately $176 million to $165–$170 million, while the commercial-start date became uncertain.
- 31% rewrittenRISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
We have incurred net losses since inception. We expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability
Annual net loss decreased from $15.1 million to $12.2 million, while limited revenue and expected future losses remain.
All 28 risk factors
Headings as the filing states them, in filing order.
RISKS RELATING TO OUR BUSINESS AND TECHNOLOGY
- 01We have incurred net losses since inception. We expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability31% rewritten
- 02We may not be able to execute our business plan or stay in business without additional funding
- 03Conditions in the financial markets and economic conditions in general may adversely affect our ability to raise additional capital, execute our business plan or remain in business
- 04Our technology may not be successful in achieving widespread commercial success at scaleNew
- 05We face business risks due to our relationships with strategic partners and other factors that may affect our joint venture endeavors
- 06If we are unable to successfully scale our manufacturing processes, we may not meet customer demand
- 07Our joint venture with Ester to construct and operate a manufacturing facility in India involves significant risks, and any delays or disruptions could adversely affect our business, financial condition, and prospects40% rewritten
Risks related to this joint venture and facility construction include, but are not limited to
- 08Failure to achieve expected operating efficiencies or projected economic returns62% rewritten
- 09We may not realize the expected benefits and may face risks associated with our licensing arrangements, and our ability to continue to generate significant revenue from technology licensing may be limited or delayed
- 10We operate in a highly competitive and rapidly evolving industry, and increased competition or technological advances could adversely affect our business, financial condition, and results of operations
- 11We are vulnerable to fluctuations in the supply and price of raw materials
- 12The loss of the services of Mr. Daniel Solomita, our President and Chief Executive Officer, and Chairman of the Board of Directors, or our failure to timely identify and retain competent personnel could negatively impact our ability to develop our business
- 13We are subject to certain risks related to litigation filed by or against us and investigations we are subject to, and adverse results may harm our business
- 14We are subject to an SEC Investigation which could have a material adverse impact on our business, financial condition, results of operation, cash flows and reputation
- 15Our failure to protect our intellectual property and proprietary technology may significantly impair our competitive advantage
- 16We may face costly intellectual property infringement claims, the result of which would decrease the amount of cash available to operate and complete our business plan
- 17We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business
- 18If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience material adverse effects on our business, financial condition, results of operations and prospects
- 19If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and the price of our common stock
- 20We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations
- 21We are subject to extensive and evolving domestic and global legal and regulatory requirements, and failure to obtain or maintain necessary approvals and comply with applicable laws could adversely affect our ability to commercialize our technology and operate our business
- 22Our current arrangements contain certain restrictions and potential cash obligations, and raising additional funds may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
- 23Trading volume in our stock can fluctuate and an active trading market for our common stock may not be available on a consistent basis to provide stockholders with adequate liquidity. Our stock price may be volatile, and our stockholders could incur significant investment losses
- 24other factors described elsewhere in these Risk Factors
- 25Our President and Chief Executive Officer and Chairman of the Board of Directors, Mr. Daniel Solomita, beneficially owns a majority of the total voting power of our capital stock, and accordingly, has control over stockholder matters, our business and management
- 26Anti-takeover effects of certain provisions of Nevada state law hinder a potential takeover of our company
- 27Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them
- 28Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities66% rewritten
Other Loop Industries 10-Ks
- FY2025 10-K risk factors29 risks
Loop Industries is an early-stage plastics technology company dependent on continuous external financing and scaling its depolymerization process. Operations face significant hurdles from ongoing SEC investigations, customer and partner concentration, and heavy dependence on CEO Daniel Solomita.
Filed May 29, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.